


# PRODUCT INFORMATION



## Mozavaptan (hydrochloride)

Item No. 16664

**CAS Registry No.:** 138470-70-9  
**Formal Name:** N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-benzamide, monohydrochloride  
**Synonym:** OPC 31260  
**MF:** C<sub>27</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub> • HCl  
**FW:** 464.0  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 288 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Mozavaptan (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the mozavaptan (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Mozavaptan (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of mozavaptan (hydrochloride) is approximately 25 mg/ml in ethanol and approximately 30 mg/ml in DMSO and DMF.

Mozavaptan (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, mozavaptan (hydrochloride) should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Mozavaptan (hydrochloride) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Mozavaptan is an orally bioavailable antagonist of vasopressin V<sub>2</sub> receptors (K<sub>i</sub> = 9.42 nM in HeLa cells expressing the human receptor).<sup>1,2</sup> It is selective for vasopressin V<sub>2</sub> over V<sub>1</sub> receptors (IC<sub>50</sub>s = 14 and 1,200 nM, respectively) in radioligand binding assays using rat kidney and rat liver membranes that endogenously express high levels of vasopressin V<sub>2</sub> and V<sub>1</sub> receptors, respectively.<sup>1</sup> Mozavaptan (10-30 mg/kg, p.o.) increases urine volume and decreases urine osmolality, indicating aquaresis, in conscious rats. It reduces decreases in urine flow and increases in urine osmolality induced by arginine vasopressin (AVP; Item No. 24154) in anesthetized rats when administered intravenously at doses ranging from 10 to 100 µg/kg.

### References

1. Yamamura, Y., Ogawa, H., Yamashita, H., *et al.* Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V<sub>2</sub> receptor antagonist. *Br. J. Pharmacol.* **105**(4), 787-791 (1992).
2. Nakamura, S., Itoh, S., Fujiki, H., *et al.* Binding affinities of mozavaptan hydrochloride (OPC-31260) for vasopressin receptors. *Pharmacol. Ther.* **34**(7), 827-834 (2006).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/20/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM